Literature DB >> 12372123

Lower airway inflammatory responses to repeated very-low-dose allergen challenge in allergic rhinitis and asthma.

M-E Boulay1, L-P Boulet.   

Abstract

BACKGROUND: Low-dose allergen challenge (LDAC) may be a useful tool for studying the capacity of allergens to induce airway inflammation in atopic subjects.
OBJECTIVE: To evaluate lower airway inflammatory changes following repeated inhalation of very low doses of allergen (VLDAC) in non-asthmatic subjects with allergic rhinitis (NAAR) compared with mild allergic asthmatic subjects (AA).
METHODS: Fourteen NAAR and 11 AA were seen out of the pollen season and had skin prick tests with common aeroallergens. Baseline spirometry (S) and methacholine challenge (MC) were done and blood and induced sputum (IS) differential cell counts were obtained. Each subject underwent VLDAC on four consecutive mornings with a relevant allergen. S, MC, and blood and IS samplings were repeated 6 h after the second and fourth VLDAC and one week later.
RESULTS: Although there were, as expected, no changes in FEV1 or PC20 in either group, mean percentage eosinophils on IS were significantly increased in NAAR on day 2 of VLDAC and decreased in all but one subject on day 4, with a tendency to return to baseline levels one week later. In AA, there was a non-significant trend for sputum eosinophils to increase on day 2; four subjects showed a decrease of eosinophils on day 4 of VLDAC. There was a correlation between eosinophil cationic protein (ECP) levels and eosinophil counts in NAAR throughout the study. There were no variations in other sputum cells or blood inflammatory cells.
CONCLUSION: VLDAC can increase the percentage of eosinophils in IS of NAAR subjects without associated respiratory symptoms nor physiological modifications. A reduction in eosinophilic response despite repeated exposure, more common in NAAR subjects, suggests an adaptation process that needs to be further evaluated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12372123     DOI: 10.1046/j.1365-2745.2002.01508.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  6 in total

1.  Clinical efficacy of recombinant human latrophilin 3 antibody in the treatment of pediatric asthma.

Authors:  Maohua Liu; Jingxiu Zhang; Chengjun Liu
Journal:  Exp Ther Med       Date:  2017-10-25       Impact factor: 2.447

2.  Comparison of circulating fibrocytes from non-asthmatic patients with seasonal allergic rhinitis between in and out of pollen season samples.

Authors:  Marie-Ève Côté; Marie-Ève Boulay; Sophie Plante; Andréanne Côté; Jamila Chakir; Louis-Philippe Boulet
Journal:  Allergy Asthma Clin Immunol       Date:  2022-03-16       Impact factor: 3.406

Review 3.  Allergen provocation tests in respiratory research: building on 50 years of experience.

Authors:  Gail M Gauvreau; Beth E Davis; Guy Scadding; Louis-Philippe Boulet; Leif Bjermer; Adam Chaker; Donald W Cockcroft; Barbro Dahlén; Wyste Fokkens; Peter Hellings; Nikolaos Lazarinis; Paul M O'Byrne; Ellen Tufvesson; Santiago Quirce; Maurits Van Maaren; Frans H de Jongh; Zuzana Diamant
Journal:  Eur Respir J       Date:  2022-08-25       Impact factor: 33.795

4.  Identification of genes expressed by human airway eosinophils after an in vivo allergen challenge.

Authors:  Stephane Esnault; Elizabeth A Kelly; Elizabeth A Schwantes; Lin Ying Liu; Larissa P DeLain; Jami A Hauer; Yury A Bochkov; Loren C Denlinger; James S Malter; Sameer K Mathur; Nizar N Jarjour
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

5.  Systemic and local eosinophil inflammation during the birch pollen season in allergic patients with predominant rhinitis or asthma.

Authors:  Mary Kämpe; Gunnemar Stålenheim; Christer Janson; Ingrid Stolt; Marie Carlson
Journal:  Clin Mol Allergy       Date:  2007-10-29

6.  Allergic Non-Asthmatic Adults Have Regional Pulmonary Responses to Segmental Allergen Challenge.

Authors:  Vanessa J Kelly; Tilo Winkler; Jose G Venegas; Mamary Kone; Daniel L Hamilos; Roshi Afshar; Josalyn L Cho; Andrew D Luster; Benjamin D Medoff; R Scott Harris
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.